Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors

Ting-Ting Li, Feng Qiu, Zhi Rong Qian, Jun Wan, Xiao-Kun Qi, Ben-Yan Wu

Abstract

Gastric neuroendocrine tumors (GNETs) are rare lesions characterized by hypergastrinemia that arise from enterochromaffin-like cells of the stomach. GNETs consist of a heterogeneous group of neoplasms comprising tumor types of varying pathogenesis, histomorphologic characteristics, and biological behavior. A classification system has been proposed that distinguishes four types of GNETs; the clinicopathological features of the tumor, its prognosis, and the patient’s survival strictly depend on this classification. Thus, correct management of patients with GNETs can only be proposed when the tumor has been classified by an accurate pathological and clinical evaluation of the patient. Here we review the literature on GNETs, and summarize the classification, clinicopathological features (especially prognosis), clinical presentations and current practice of management of GNETs. We also present the latest findings on new gene markers for GNETs, and discuss the effective drugs developed for the diagnosis, prognosis and treatment of GNETs.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Gastric neuroendocrine tumor; Classification; Clinicopathological significance; Diagnosis; Prognosis; Treatment

Core tip: Gastric neuroendocrine tumors (GNETs) comprise distinct tumor entities that have been classified on the basis of pathogenesis and histomorphologic characteristics into 4 types that differ in biological behavior and prognosis. To plan the correct management and optimal therapeutic approach in patients with GNETs, it is essential to obtain an adequate clinical evaluation and assessment of the pathological features of the tumor. Development of new gene markers as well as effective drugs is expected for the better diagnosis, prognosis and treatment of GNETs.

Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20(1): 118-125 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i1/118.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i1.118

INTRODUCTION

Gastric neuroendocrine tumors (GNETs) are rare tumors, occurring in 1 to 2 cases/1000000 persons per year, and accounting for 8.7% of all gastrointestinal neuroendocrine tumors[1]. However, over the last 50 years, the incidence of GNETs has increased in most countries, in part because of better awareness and more widespread...
use of upper gastrointestinal endoscopy\(^2\). Gastric neuroendocrine carcinoma has also been recently reported in a patient with long-term use of a proton pump inhibitor\(^3\). GNETs are classified into four types, based on pathogenesis and histomorphologic characteristics; these types differ in biological behavior and prognosis\(^4\), ranging from benign to highly malignant biological behavior and extremely poor prognosis\(^5\). Novel strategies for treating GNETs have been developed recently.

**CLASSIFICATION**

The four GNET subgroups are listed in Table 1. Classification is based primarily on their clinicopathological features\(^6\). Type I GNET is mostly related to chronic atrophic gastritis, reflected by the presence of multiple small neoplasms; it has an excellent prognosis after resection\(^8\). Because of its low metastatic potential, type I GNET is the most benign type, with death from metastatic disease reported in only three patients out of 724 cases reviewed; however, despite their generally benign course, the malignant potential of type I GNET should not be ignored when planning the medical workup of these patients\(^9\). Type II GNET is histologically similar to type I, and is usually associated with MEN1 syndrome or Zollinger-Ellison syndrome\(^10\). It is also usually considered to be benign, with a low risk of malignancy\(^11\). Type III GNET is a solitary sporadic tumor that quite often infiltrates the muscularis propria and serosa; it is usually not associated with other gastric conditions or hypergastrinemia and frequently presents as a large lesion, greater than 10 mm in size, which is well-differentiated, and is accompanied by angioinvasion and lymph node and liver metastases, resulting in a poor prognosis\(^12\). Type IV GNET is an uncommon tumor, and usually is single, large, poorly differentiated, and highly malignant; it is typically accompanied by vascular invasion and metastases, and has an extremely poor prognosis\(^13\).

Types I to III GNETs are comprised of enterochromaffin-like (ECL) cells, while type IV consists of other types of endocrine cell tumors (that secrete serotonin, gastrin, or adrenocorticotropic hormone), poorly differentiated endocrine carcinomas, and mixed endocrine-exocrine tumors\(^14\). Well-differentiated tumors generally originate from ECL cells that are located in the corpus/fundus mucosa of the stomach, and represent the major proliferative target of gastrin, which is considered to be the main stimulus for the growth both of type I and type II GNETs. On the contrary, type III and type IV GNETs are “gastrin-independent”.

**CLINICOPATHOLOGICAL FEATURES**

**Type I GNET**

Seventy to eighty percent of gastric GNETs are type I tumor and they are usually less than 10 mm in diameter, multiple, mostly related to chronic atrophic gastritis, and localized in the gastric fundus or body\(^15\). The histological features show a typical GNET, a trabecular or solid arrangement. Tumor cells are monomorphic and medium sized, of regular shape with round nuclei. Mitoses are either absent or are seen occasionally. Tumor extension is limited to the mucosa or submucosa. The gastrin-dependent GNETs are consistently associated with generalized proliferation of endocrine cells in the extratumoral fundic mucosa. A histopathological classification has been formulated for the spectrum of proliferative lesions presented by fundic endocrine cells of hypergastrinemic patients; it arranges type I tumors in a sequence presumed to reflect the temporal evolution of the process and the increasing oncologic risk for patients\(^16\).

Diagnosis of GNETs requires efficient histopathological, biochemical and diagnostic imaging analyses\(^17\). Most type I tumor cells are strongly positive for endocrine markers such as chromogranin A (CgA), neuron-specific enolase (NSE), and vesicular monoamine transporter 2, which characterize the cells as histamine-producing cells. Once the diagnosis of a type I GNET is suspected, determination of CgA expression can be helpful. However, the concentration of CgA correlates with the number of ECL cells; thus, a pathologically high CgA concentration is neither pathognomonic nor essential for the diagnosis of type I GNET. The proliferation marker Mki67 is typically expressed in less than 2% of the tumor cells. Patients are usually asymptomatic, with diagnosis usually occurring during gastroscopy. Destruc-

### Table 1 Features of gastric neuroendocrine tumors

| Type | GNET | Proportion of GNETs | Tumor features | Risk of metastases | Tumor-related death | Proliferation (Ki67) | Immunohistochemistry | Histology |
|------|------|---------------------|----------------|-------------------|---------------------|---------------------|----------------------|-----------|
| Type I GNET | | 70%-80% | Usually multiple, small (1-2 cm), polypoid or intramucosal | 2%-5% | < 0.5% | < 2% | CgA positive, NSE, VMAT 2 positive | Mitoses (absent or occasionally) |
| Type II GNET | | 5%-6% | Usually multiple, small (1-2 cm), polypoid | 10%-30% | < 5% | < 2% | CgA positive | Mitoses < 1 per 2 HPFs |
| Type III GNET | | 14%-25% | Single, large (> 2 cm, mean 5.1 cm) | 50%-100% | Well-differentiated: 25%-30%, poorly differentiated: 75%-87% | > 2% | CgA negative | Mitoses > 1 per HPF |
| Type IV GNET | | Rare | Single, large (largest 16 cm) | 100% | | | CgA negative | Severe grade 3 histology |

GNET: Gastric neuroendocrine tumor; CgA: Chromogranin A; NSE: Neuron specific enolase; VMAT: Vesicular monoamine transporter; HPF: High power field.
tion of parietal cells from longstanding chronic atrophic gastritis may lead to reduced intrinsic factor secretion and consequently to an impaired resorption of vitamin B12; thus, vitamin B12 deficiency and hyperchromic macrocytic anemia are often associated with autoimmune atrophic gastritis and hypergastrinemia. Type I GNET is very rarely metastatic (5% to local lymph nodes; less than 2% showing distant metastases), with no related deaths and a reported long-term survival rate of 100%.[23-25] Thus, initial staging is recommended. Endoscopic ultrasound can be helpful to demonstrate localized disease, i.e., lack of submucosal infiltration, while an upper abdominal computed tomography (CT) scan could aid in detecting metastatic hepatic disease. Depending on the size and number of the lesions, endoscopic tumor resection is the treatment of choice.[26] Netazepide (YF476) is a potent and highly selective cholecystokinin 2 receptor antagonist of the benzodiazepine class.[27] It is an orally active, highly selective and competitive antagonist of gastrin receptors.[28] Netazepide is a tool used to study the physiology and pharmacology of gastrin, and merits application in patients, to assess its potential to treat gastric acid-related conditions and the trophic effects of hypergastrinemia.[29] Although repeated doses of netazepide lead to tolerance with regard to the drug’s effect on pH, the accompanying increase in plasma gastrin is consistent with continued inhibition of acid secretion by antagonism of the gastrin receptor and by gene up-regulation.[30] It was reported that treatment of GNET type I with YF476 results in regression of the tumor and normalization of serum chromogranin A.[31] Ravizza et al.[32] recommend use of endoscopic/histochemical examination to follow patients with type I GNET, along with an annual abdominal ultrasound scan; and that endoscopic ultrasonography, CT and somatostatin receptor scintigraphy be reserved for lesions with a diameter greater than 10 mm, or when clinically indicated to plan an adequate endoscopic/surgical resection of the lesions. However, despite their generally benign course, type I GNET may have malignant potential, a finding that should be considered when planning the medical workup of these patients.[33]

Type II GNET

Five to six percent of GNETs reportedly are type II tumors, which occur as a result of a gastrin-secreting neoplastic tissue in Zollinger-Ellison syndrome. Clinically, type II GNET behaves similarly to the type I tumors described above, with small (1-2 cm), multiple, and well-differentiated lesions. The proliferation marker MKI67 is expressed in < 2% of the tumor cells. Endocrine markers such as CgA are increased in type II GNET, but this may be due to other manifestations of a GINET.[34] Type II GNET is usually limited to the mucosa and/or submucosa, with metastases seen in ten to thirty percent, and tumor-related death in less than 5% of cases, according to the literature.[35] Tumors show moderately enlarged lobules and trabeculae, and moderate cellular atypia, which include nuclear polymorphism, hyperchromasia, prominent nucleoli, and a slight increase in mitotic count, < 1 per 2 high power fields (HPFs). Small regions of necrosis may also be visible.[36] The diagnosis is usually made by gastroscopy. In addition to endoscopic resection, the somatostatin analog octreotide induces tumor regression and a marked decrease in plasma gastrin levels; the medical approach plays a key role in the management of patients with type II GNET, because of the presence of multiple tumors that are not amenable to endoscopic excision.[37]

Type III GNET

Fourteen to twenty-five percent of GNETs are classified as type III, and are non-gastrin dependent, large (> 2 cm, mean 5.1 cm), usually occur singly, and grow from the gastric body/fundus in the context of a normal (non-atrophic) surrounding mucosa.[38] Type III GNET is considered to be an aggressive cancer, associated with deep invasion and metastases, and has a poor prognosis. Typically, more than 2% of tumor cells express the proliferation marker MKI67 but are negative for CgA. Histologically, this type of tumor is characterized by large, poorly defined, solid aggregates or diffuse sheets of round or spindle-shaped cells. Abundant mitoses are detected (> 1 per HPF)[39], and focal necrosis is common. Ultrastructural studies document the presence of endocrine granules. Whenever possible, surgical resection and lymph node dissection are the treatment of choice.[40] Depending on local growth characteristics of malignant type III tumors, this could include extended radical surgery including gastric resection and regional lymphadenectomy.[41]

Type IV GNET

Type IV GNET is uncommon, large, poorly differentiated tumors that occur singly and are highly malignant.[42] The largest known type IV GNET was reported by Bordi et al.[43] to be 16 cm. In most cases, type IV GNET shows lympho invasion, angioinvasion, and deep wall invasion at the time of diagnosis. Poorly differentiated type IV GNETs display a severe histology, with a prevalent solid structure, abundant central necrosis, and severe cytological atypia with frequent atypical mitoses and high levels of MKI67 (> 30). CgA is normally absent or expressed only focally, consistent with the rare electron-dense granules observed ultrastructurally, while synaptophysin and the cytosol markers NSE and PGP9.5 are diffusely and strongly expressed.[44] Although rare, the poorly differentiated type IV GNETs deserve particular attention owing to their aggressive nature and extremely poor prognoses - mean survival of 6.5 to 14.9 mo have been reported.[45] Surgical resection is the most appropriate form of treatment for this type of tumor. Multi-drug chemotherapy is promising, but remains to be evaluated in larger clinical studies.[46] Type IV GNET demands an aggressive surgical approach followed by chemotherapy and multimodality adjuvant therapy.[47]
Table 2  New tissue and serum tumor markers for specific diagnostics and prognostics of gastric neuroendocrine tumors

| Ref.                  | Case | Hormones, amines and peptides for specific diagnostic and prognostics of GNETs | Expression                     |
|----------------------|------|---------------------------------------------------------------------------------|--------------------------------|
| Giandomenico et al.  | 15   | CD133                                                                           | 20% positive                   |
| Mia-Jan et al.       | 2    | ISL1                                                                            | Complete loss                  |
| Agaimy et al.        | 1    | c-kit                                                                           | Oversuppression                |
| Mori et al.          | 5    | Cyclin E                                                                        | Independent prognostic factor  |
| Namikawa et al.      | 5    | Chromogranin A                                                                  | 40% positive                   |
|                      |      | Synaptophysin                                                                   | 60% positive                   |
|                      |      | p53                                                                              | 100% positive                  |

GNET: Gastric neuroendocrine tumor; ISL1: Islet-1.

**NEW TISSUE AND SERUM TUMOR MARKERS FOR SPECIFIC DIAGNOSTICS AND PROGNOSTICS OF GNETS**

Tumor biomarkers or molecular markers that predict patient outcome are being discovered for increasing numbers of tumors. Tumor markers that are specific for GNETs include Histamine, Gastrin, gastrin-releasing peptide, Ghrelin, and Obestatin. Mia-Jan et al[41] evaluated the expression of CD133 in GNETs (n = 15) and found that it was strongly expressed in about 20% of GNETs. It is expressed in poorly differentiated as well as in well-differentiated GNETs. The human insulin gene enhancer-binding protein islet-1 (ISL1) is a transcription factor involved in the differentiation of the neuroendocrine pancreatic cells and recent studies have identified it as a marker for well-differentiated pancreatic neuroendocrine neoplasms. Agaimy et al[44] showed that ISL1 is expressed in endocrine cells of the normal stomach and colorectal tissue, in contrast to the complete loss of this protein in some gastrointestinal neuroendocrine carcinomas (n = 2), similar to the distribution of this protein in normal and neoplastic pancreatic tissues. In addition, Mori et al[45] report the presence of focal neuroendocrine differentiation and diffuse c-kit overexpression in a case of gastric undifferentiated carcinoma: immunohistochemistry shows that the tumor cells are diffusely positive for cytokeratin, vimentin, and c-kit, and focaly positive for CgA and synaptophysin. These authors hypothesized that c-kit overexpression in these tumor cells can be attributed to neuroendocrine differentiation. To characterize the expression of the proteins cyclin D1, cyclin E and P53 in gastroenteropancreatic neuroendocrine tumors and assess their prognostic impact, tumor specimens from 68 patients (including 51 cases of gastric tumor origin, with a complete follow-up) were studied immunohistochemically for cyclin D1, cyclin E and P53 expression, but no significant correlation was found between the expression of cyclin D1 and any clinicopathological variables. Results from Agaimy and colleagues indicate a prognostic relevance for cyclin E and P53 immunoreactivity: cyclin E may be an independent prognostic factor from the 2010 WHO Classification, and it should be evaluated in further studies[46]. In a study cohort of GNETs, it was reported that positive rates of neuroendocrine markers were 40% for chromogranin A, 60% for synaptophysin, 60% for CD56, 40% for neuron-specific enolase, and 100% for p53 protein[41]. Table 2 summarizes new tissue and serum tumor markers for specific diagnostics and prognostics of GNETs.

**TREATMENTS DEVELOPMENT**

The only curative therapy for GNETs is the complete resection of the tumor. Regardless of type, endoscopic resection is recommended as an initial treatment of NETs that are not yet at the advanced stages; if this is not possible, minimally invasive surgery that involves wedge resection should be considered as an alternative. However, while endoscopic submucosal dissection (ESD) or local resection can be performed in early stage tumors, radical surgery with lymph node dissection is recommended for all advanced GNETs[47,48]. The present study indicates that because of complete resection, ESD may reasonably serve as a radical treatment for GNETs when lesions are within the existing criteria. In addition, endoscopic treatment can be also considered in patients with a high risk of perioperative complications due to age or advanced comorbidity: for example, if other contraindications to major surgery exist, ESD would be the treatment of choice, even when lesions are little beyond the existing criteria[41].

Complete surgical resection is associated with better long-term survival[49]. Many case series have recently been published that advocate antrectomy as a means of gastrin suppression in type I GNET[49,50]. While there is universal consensus on the use of surgical treatment of type III GNET, current options for type I and II GNETs include simple surveillance, endoscopic polyectomy, surgical excision with or without surgical antrectomy, or total gastrectomy[32].

Chemotherapy is a palliative option for patients with type IV GNET, and is reserved for those with significant symptoms related to advanced disease, or with a poor prognosis (related to poor tumor differentiation, rapid disease progression, or progression on somatostatin analogues)[53]. Response rates to single-agent chemotherapy are low, so combination chemotherapy regimens are most commonly administered. Interferon-α (IFN-α) is also effective in decreasing symptoms associated with secretion of peptides by the tumor in 30%-70% of patients with GNETs. However, the onset of effect of IFN-α is delayed, and adverse effects (including fever, fatigue, weight loss, and anorexia) may be significant and are dose dependent. Combination chemotherapy, such as
etoposide+cisplatin (CDDP)/carboplatin, is a useful medical treatment for unresected NET, and the somatostatin analogues octreotide and pasireotide (SOM230) reportedly provide the benefit of hormonal symptom control as well as suppression of tumor growth. Somatostatin, a naturally occurring regulatory hormone that binds to somatostatin receptors and inhibits tumor secretion of regulatory peptides, is another palliative treatment. Although there are no standard chemotherapy regimens for GNETs that use these receptors, treatment with CDDP plus irinotecan (CPT-11) is effective against this disease, with an overall response rate of 75% and a progression-free survival of 212 d.

Patients with type IV GNET have reportedly benefited from targeted radiotherapy. Recently, the effect of 177Lu-octreotate (177Lu), administered in repeated doses of 100-200 mCi, with intervals of 6-9 wk up to a final cumulative dose of 600-800 mCi, was investigated in 131 patients with GNETs. The shorter range for 177Lu in tissues may indicate that this isotope is better for treatment of smaller tumors, while 90Y might be more suitable for larger ones. Since metastases often are of varying size, the best option may be to combine 117Lu- and 90Y-labelled somatostatin analogues. Targeted irradiation therapy involving the use of selective internal radiation therapy, which has been used in patients with primary hepatocellular cancer and metastatic colorectal cancer, was recently tried in patients with GNETs: preliminary results are encouraging, but further studies are warranted. Grin reports that anti- Helicobacter pylori drugs may be helpful in treating patients with duodenal gastrinoma with multiple GNETs secondary to chronic Helicobacter pylori-induced gastritis.

Novel principles for treating cancer patients, such as inhibition of angiogenesis, or molecular targeting of growth factor receptors, have been developed recently. For example sunitinib, an oral tyrosine kinase inhibitor that inhibits VEGFR, is generally well tolerated. Imatinib, another tyrosine kinase inhibitor that selectively inhibits PDGFR, was also tried in patients with various NETs without any objective responses, and causing significant toxicity. New diagnostic techniques have led to increasingly early recognition of early gastrointestinal NETs. Most patients with early, well differentiated NETs can be treated conservatively, and followed by endoscopic surveillance. Note that patients with (previous) NET/carcinoid disease have a 15%-25% risk for second malignancies in the breast, prostate, colorectum. Such carcinomas demand an aggressive surgical approach followed by chemotherapy and multimodal adjuvant therapy, and randomized, prospective clinical trials that include a search focused on MKI67 labeling index are required to demonstrate an unequivocal survival advantage for patients who receive chemotherapy or radiation therapy after resection of NETs. Table 3 summarizes medical treatment for patients with GNETs.

**CONCLUSION**

GNETs comprise distinct tumor entities that have been classified on the basis of pathogenesis and histomorphologic characteristics into 4 types that differ in biological behavior and prognosis. To plan the correct management and optimal therapeutic approach in patients with GNETs, it is essential to obtain an adequate clinical evaluation and assessment of the pathological features of the tumor. Patients who are diagnosed with NETs early and accurately have a greater chance for complete cure. Over the past two decades, there has been a major turnover in diagnostic methods. In a word, development of new gene marker as well as effective drugs is expected for the better diagnosis, prognosis and treatment of GNETs.
and serotonin-producing gastric carcinoid. J Gastrointest Cancer 2012; 43: 319-322 [PMID: 21424696 DOI: 10.1007/s12029-011-9275-z]

18 Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2: S94-597 [PMID: 10604110]

19 Yu JY, Wang LP, Meng YH, Hu M, Wang JL. Bordi C. Classification of gastric neuroendocrine tumors and its clinicopathologic significance. World J Gastroenterol 1998; 4: 158-161 [PMID: 11819263]

20 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72 [PMID: 18178188 DOI: 10.1016/S1470-4247(07)70410-2]

21 Strosberg JR, Nasir A, Hodul P, Kvosl L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointestinal Cancer Res 2008; 2: 113-125 [PMID: 19259290]

22 Oberg K, Jelic S. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 150-153 [PMID: 19454440 DOI: 10.1093/annonc/mdp158]

23 Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O'Toole D, Reynolds VJ. Gastric neuroendocrine tumours. Dig Surg 2012; 29: 331-348 [PMID: 23075625 DOI: 10.1159/000342988]

24 Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32 [PMID: 14687136]

25 Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D, Crosta C. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis 2007; 39: 537-543 [PMID: 17433795 DOI: 10.1016/j.dld.2007.01.018]

26 Pflöckinger U. Diagnosis and treatment of gastric neuroendocrine tumours. Wien Klin Wochenschr 2007; 119: 570-572 [PMID: 17985089 DOI: 10.1016/j.kwer.2007.01.018]

27 Delle Fave G, Capurso G, Annibale B, Panzuto F. Gastric neuroendocrine tumours. Neuroendocrinology 2004; 80 Suppl 1: 16-19 [PMID: 15477710 DOI: 10.1159/000080734]

28 Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumour development. Regul Pept 2010; 162: 52-60 [PMID: 20144901 DOI: 10.1016/j.regpep.2010.01.009]

29 Boyce M, David O, Darvishy K, Mitchell T, Johnston A, Warrington S. Single oral doses of netazepide (YF476), a gastric receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 181-189 [PMID: 22667579 DOI: 10.1111/j.1365-2036.2012.05143.x]

30 Boyce M, Warrington S, Black J. Netazepide, a gastric/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 649-658 [PMID: 23432534 DOI: 10.1111/bcp.12099]

31 Boyce M, Warrington S. Effect of repeated doses of netaze-pide, a gastrin receptor antagonist, omeprazole and placebo on 24h gastric acidity and gastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 680-688 [PMID: 23452415 DOI: 10.1111/bcp.12099]

32 Fossmark R, Sardal O, Janus CS, Vqvistad G, Nordrum IS, Boyce M, Waldum HL. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36: 1067-1075 [PMID: 23072686 DOI: 10.1111/apt.12090]

33 Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751 [PMID: 15887161]
Xie SD, Wang LB, Song XY, Pan T. Minute gastric carcinoid tumor with regional lymph node metastasis: a case report and review of literature. World J Gastroenterol 2004; 10: 2461-2463 [PMID: 15285046]

Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343: 551-554 [PMID: 10954763 DOI: 10.1056/NEJM20000824430805]

Hosoya Y, Nagai H, Koinuma K, Yasuda Y, Kaneko Y, Saito K. A case of aggressive neuroendocrine carcinoma of the stomach. Gastric Cancer 2003; 6: 55-59 [PMID: 12673427 DOI: 10.1007/s101200300007]

Rindi G, Klöppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80 Suppl 1: 1-15 [PMID: 15477709 DOI: 10.1159/000080733]

Kidd M, Gustafsson Bl. Management of gastric carcinoids (neuroendocrine neoplasms). Curr Gastroenterol Rep 2012; 14: 467-472 [PMID: 22976575 DOI: 10.1007/s11894-012-0049-x]

Bordi C, Falchetti A, Azzoni C, D’Adda T, Canavese G, Guariglia A, Santini D, Tomassetti P, Brandi ML. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 1997; 21: 1075-1082 [PMID: 9289884]

Waisberg J, de Matos LL, do Amaral Antonio Mader AM, Pezzolo S, Eher EM, Capelozzi VL, Speranzini MB. Neuroendocrine gastric carcinoma expressing somatostatin: a highly malignant, rare tumor. World J Gastroenterol 2006; 12: 3944-3947 [PMID: 16804989]

Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol 2013; 46: 34-40 [PMID: 23306663 DOI: 10.1159/000348332]

Mia-Jan K, Munkhdelger J, Lee MR, Ji SY, Kang TY, Choi E, Cho MY. Expression of CD113 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis. Tumori 2013; 99: 229-309 [PMID: 23154555]

Agaimy A, Erlenbach-Wünsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Ferren A, Klöppel G. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Med Pathol 2013; 26: 995-1003 [PMID: 23503646 DOI: 10.1016/j.medpat.2013.06.073]

Mori D, Akashi M, Baba K, Morito K, Shibaki M, Hashimoto M, Nakamura A, Mawata S, Sato S. Gastric undifferentiated carcinoid tumor with diffuse c-kit overexpression and focal neuroendocrine differentiation. Pathol Res Pract 2013; 209: 132-134 [PMID: 23347914 DOI: 10.1016/j.prp.2012.02.004]

Liu SZ, Zhang F, Chang YX, Ma J, Li X, Li XH, Fan JH, Duan GC, Sun XB. Prognostic impact of cyclin D1, cyclin E and P53 on gastroenteropancreatic neuroendocrine tumors. Asian Pac J Cancer Prev 2013; 14: 419-422 [PMID: 23534765]

Kim BS, Oh ST, Yook JH, Kim KC, Kim MG, Jeong JW, Kim BS. Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. Am J Surg 2010; 200: 328-333 [PMID: 20385369 DOI: 10.1016/j.amjsurg.2009.10.028]

Goretzki PE, Starke A, Akca A, Lammers BJ. Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET). Internist (Berl) 2012; 53: 152-160 [PMID: 22920318 DOI: 10.1007/s00108-011-2917-1]

Ahlem H, Wängberg B, Jansson S, Friman S, Olausson M, Tylen U, Nilsson O. Interventional treatment of gastroenteropancreatic neuroendocrine tumors. Digestion 2000; 62 Suppl 1: 59-68 [PMID: 10940689]

Hoshino M, Omura N, Yano F, Tsuboi K, Matsumoto A, Yamamoto SR, Akimoto S, Kashiwagi H, Yanaka K. Usefulness of laparoscopic-assisted resection for gastric carcinoids with hypergastrinemia. Hepatogastroenterology 2010; 57: 379-382 [PMID: 20583484]

Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic resection for the treatment of type I gastric carcinoid tumors. J Surg Oncol 2010; 162: 22-25 [PMID: 20421108 DOI: 10.1016/j.jskos.2010.01.005]

Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract 2012; 2012: 287825 [PMID: 23316222 DOI: 10.1155/2012/287825]

Plockinger U, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451 Suppl 1: S71-S80 [PMID: 17684765 DOI: 10.1002/srp.00428-005-0464-2]

Oberg K, Kvals L, Caplin M, Delle Fave G, de Herder WW, Rindi G, Ruzsniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973 [PMID: 15151956]

Grande C, Haller DG. Gastrointestinal stromal tumors and neuroendocrine tumors. Semin Oncol Nurs 2009; 25: 48-60 [PMID: 19217505 DOI: 10.1016/j.soncn.2008.10.004]

Pusceddu S, Milione M, Procopio C. Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. Oncol Res 2011; 19: 403-406 [PMID: 22329200]

Okita NT, Kato K, Takahari D, Hiroshima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Tani-guchi H, Shirao K. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gas-tric Cancer 2011; 14: 161-165 [PMID: 21327441 DOI: 10.1007/s10120-011-0025-5]

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med Mol Imaging 2001; 28: 1421-1429 [PMID: 11585303]

Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Nucl Med Mol Imaging 2007; 34: 405-408 [PMID: 17073934 DOI: 10.1007/s00259-006-0296-9]

Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, van Eijck CH. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001; 88: 31-40 [PMID: 11136306 DOI: 10.1046/j.1365-2168.2001.01644.x]

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43: 610-616 [PMID: 11994522]

Buscombe JR, Caplin ME, Hillman AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44: 1-6 [PMID: 12515868]

Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA. Iodine-131 metaiodo-benzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004; 101: 1987-1993 [PMID: 15455358]
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762 [PMID: 15837990 DOI: 10.1200/JCO.2005.08.066]

Granberg D, Oberg K. Neuroendocrine tumours. Cancer Chemother Biol Response Modif 2005; 22: 471-483 [PMID: 16110625]

Kim JY, Hur H, Cho YK, Han SU. Clinicopathologic significance of gastric adenocarcinoma with neuroendocrine features. J Gastric Cancer 2011; 11: 195-199 [PMID: 22324009 DOI: 10.5230/jgc.2011.11.4.195]

Grin A, Kim YI, Mustard R, Streutker CJ, Riddell RH. Duodenal gastrinoma with multiple gastric neuroendocrine tumors secondary to chronic Helicobacter pylori gastritis. Am J Surg Pathol 2012; 36: 935-940 [PMID: 22588069 DOI: 10.1097/PAS.0b013e31824bacb2]

Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-6118 [PMID: 15447997 DOI: 10.1158/1078-0432.CCR-04-0422]

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410 [PMID: 18612155 DOI: 10.1200/JCO.2007.15.9020]

Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006; 13: 535-540 [PMID: 16728580 DOI: 10.1677/erc.1.01124]

Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 2011; 3: 133-139 [PMID: 21860882 DOI: 10.4253/wjge.v3.i7.133]

P-Reviewers: Eghtesad B, Marinho RT  S-Editor: Ma YJ  L-Editor: Wang TQ  E-Editor: Wang CH
